Characterization of effector T cells in dry eye disease.

Jaafar El Annan, Sunil K Chauhan, Tatiana Ecoiffier, Qiang Zhang, Daniel R Saban, Reza Dana
Author Information
  1. Jaafar El Annan: Schepens Eye Research Institute, Boston, MA 02114, USA.

Abstract

PURPOSE: Dry eye disease (DED) is associated with ocular surface inflammation that is thought to be mediated primarily by CD4 T cells. The purpose of this study was to investigate whether this T cell-mediated immune response is generated in the lymphoid compartment and to characterize the functional phenotype of the T cells activated in DED.
METHODS: DED was induced in female C57BL/6 mice by exposure to a desiccating environment in the controlled environment chamber and to systemic scopolamine. T cells from regional draining lymph nodes (LNs) of DED mice and normally sighted mice were analyzed for surface activation markers (CD69 and CD154), chemokine and cytokine receptors, and proliferation potential.
RESULTS: Draining LNs of DED mice showed increased frequencies of CD69- and CD154-expressing T cells with higher proliferative capacity. In addition, these LN T cells primarily showed a helper T-cell (Th)1 phenotype, expressing significantly higher levels of IFN-gamma and IL-12Rbeta2 but not IL-4R. Similarly, the LNs of DED mice showed significantly increased frequencies of T cells expressing CXCR3 and CCR5, but not CCR4, suggesting a bias toward a Th1 phenotype.
CONCLUSIONS: These data demonstrate that a Th1-type immune response is induced in the regional LNs of DED mice. The identification of specific cytokine/chemokine receptors overexpressed by these T cells may signify potential novel targets/strategies for the treatment of DED.

References

  1. J Exp Med. 2002 Jan 21;195(2):259-68 [PMID: 11805152]
  2. J Immunol. 2006 Apr 1;176(7):3950-7 [PMID: 16547229]
  3. Arch Ophthalmol. 2006 May;124(5):710-6 [PMID: 16682594]
  4. Curr Eye Res. 1999 Sep;19(3):201-11 [PMID: 10487957]
  5. Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2553-60 [PMID: 17525184]
  6. J Immunol. 1999 Jan 1;162(1):352-8 [PMID: 9886406]
  7. Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4293-301 [PMID: 15557435]
  8. Trends Immunol. 2005 Mar;26(3):136-40 [PMID: 15745855]
  9. J Immunol. 2008 Apr 1;180(7):4714-21 [PMID: 18354195]
  10. Science. 1994 Jan 14;263(5144):235-7 [PMID: 7904381]
  11. Nat Med. 2004 Aug;10(8):813-5 [PMID: 15235599]
  12. Am J Ophthalmol. 2007 Mar;143(3):409-15 [PMID: 17317388]
  13. J Exp Med. 1993 Apr 1;177(4):1199-204 [PMID: 8096238]
  14. Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2609-14 [PMID: 12147592]
  15. Curr Opin Immunol. 2006 Dec;18(6):670-5 [PMID: 17010592]
  16. Genome Biol. 2001;2(7):RESEARCH0022 [PMID: 11516335]
  17. J Exp Med. 1997 Mar 3;185(5):825-31 [PMID: 9120388]
  18. Invest Ophthalmol Vis Sci. 2005 Aug;46(8):2766-71 [PMID: 16043849]
  19. Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2561-9 [PMID: 17525185]
  20. J Clin Invest. 1996 Aug 1;98(3):826-37 [PMID: 8698875]
  21. Mult Scler. 2000 Apr;6(2):61-5 [PMID: 10773848]
  22. Transplant Proc. 2006 Dec;38(10):3221-4 [PMID: 17175228]
  23. Science. 1993 Apr 23;260(5107):547-9 [PMID: 8097338]
  24. Mini Rev Med Chem. 2007 Nov;7(11):1089-96 [PMID: 18045212]
  25. J Neuroimmunol. 2001 Mar 1;114(1-2):242-52 [PMID: 11240038]
  26. Cell Mol Life Sci. 1999 Sep;55(12):1610-25 [PMID: 10526578]
  27. J Clin Invest. 1997 Nov 1;100(9):2404-14 [PMID: 9410920]
  28. J Immunol. 2007 Sep 15;179(6):3672-9 [PMID: 17785803]
  29. Invest Ophthalmol Vis Sci. 2001 Sep;42(10):2283-92 [PMID: 11527941]
  30. Invest Ophthalmol Vis Sci. 2001 May;42(6):1293-8 [PMID: 11328742]
  31. Science. 1997 Apr 25;276(5312):604-7 [PMID: 9110981]
  32. Ophthalmology. 1982 Oct;89(10):1173-80 [PMID: 6218459]
  33. Arch Ophthalmol. 2008 Feb;126(2):219-25 [PMID: 18268213]
  34. Cornea. 1990 Apr;9(2):170-3 [PMID: 2328584]
  35. Annu Rev Immunol. 1998;16:111-35 [PMID: 9597126]
  36. J Immunol. 2008 Jan 1;180(1):122-9 [PMID: 18097011]
  37. Am J Pathol. 2005 Jan;166(1):61-71 [PMID: 15632000]
  38. Nat Immunol. 2001 Feb;2(2):123-8 [PMID: 11175804]

Grants

  1. R01 EY020889/NEI NIH HHS

MeSH Term

Animals
Antigens, CD
Antigens, Differentiation, T-Lymphocyte
CD40 Ligand
Disease Models, Animal
Dry Eye Syndromes
Enzyme-Linked Immunosorbent Assay
Female
Flow Cytometry
Immune System
Immunophenotyping
Lectins, C-Type
Lymph Nodes
Lymphocyte Activation
Mice
Mice, Inbred C57BL
Receptors, Chemokine
Receptors, Cytokine
Th1 Cells

Chemicals

Antigens, CD
Antigens, Differentiation, T-Lymphocyte
CD69 antigen
Lectins, C-Type
Receptors, Chemokine
Receptors, Cytokine
CD40 Ligand

Word Cloud

Created with Highcharts 10.0.0TDEDcellsmiceLNsphenotypeshowedeyediseasesurfaceprimarilyimmuneresponseinducedenvironmentregionalreceptorspotentialincreasedfrequencieshigherexpressingsignificantlyPURPOSE:DryassociatedocularinflammationthoughtmediatedCD4purposestudyinvestigatewhethercell-mediatedgeneratedlymphoidcompartmentcharacterizefunctionalactivatedMETHODS:femaleC57BL/6exposuredesiccatingcontrolledchambersystemicscopolaminedraininglymphnodesnormallysightedanalyzedactivationmarkersCD69CD154chemokinecytokineproliferationRESULTS:DrainingCD69-CD154-expressingproliferativecapacityadditionLNhelperT-cellTh1levelsIFN-gammaIL-12Rbeta2IL-4RSimilarlyCXCR3CCR5CCR4suggestingbiastowardTh1CONCLUSIONS:datademonstrateTh1-typeidentificationspecificcytokine/chemokineoverexpressedmaysignifynoveltargets/strategiestreatmentCharacterizationeffectordry

Similar Articles

Cited By